OPKO Health (NASDAQ:OPK) CEO Phillip Md Et Al Frost Acquires 580,000 Shares of Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 580,000 shares of OPKO Health stock in a transaction on Friday, November 21st. The stock was acquired at an average price of $1.33 per share, with a total value of $771,400.00. Following the completion of the purchase, the chief executive officer directly owned 216,706,448 shares of the company’s stock, valued at approximately $288,219,575.84. The trade was a 0.27% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Wednesday, November 19th, Phillip Md Et Al Frost purchased 580,000 shares of OPKO Health stock. The shares were acquired at an average price of $1.31 per share, for a total transaction of $759,800.00.
• On Tuesday, November 18th, Phillip Md Et Al Frost purchased 533,300 shares of OPKO Health stock. The shares were acquired at an average price of $1.27 per share, for a total transaction of $677,291.00.
• On Friday, October 31st, Phillip Md Et Al Frost acquired 150,000 shares of OPKO Health stock. The stock was acquired at an average cost of $1.42 per share, with a total value of $213,000.00.

OPKO Health Stock Up 1.5%

NASDAQ:OPK traded up $0.02 during trading hours on Friday, reaching $1.32. The company’s stock had a trading volume of 3,296,073 shares, compared to its average volume of 3,371,171. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.41 and a quick ratio of 3.02. The company has a market cap of $1.01 billion, a price-to-earnings ratio of -5.28 and a beta of 1.50. OPKO Health, Inc. has a one year low of $1.11 and a one year high of $2.04. The business’s 50-day moving average is $1.44 and its 200-day moving average is $1.37.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.05. The company had revenue of $151.67 million during the quarter, compared to analysts’ expectations of $165.74 million. OPKO Health had a negative return on equity of 13.62% and a negative net margin of 28.10%.The business’s quarterly revenue was down 12.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.03 earnings per share. Equities research analysts predict that OPKO Health, Inc. will post -0.25 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in shares of OPKO Health by 1.0% during the first quarter. Vanguard Group Inc. now owns 29,500,071 shares of the biotechnology company’s stock valued at $48,970,000 after buying an additional 293,740 shares during the last quarter. Sculptor Capital LP bought a new position in OPKO Health during the first quarter valued at about $21,111,000. Geode Capital Management LLC raised its holdings in OPKO Health by 23.7% in the 2nd quarter. Geode Capital Management LLC now owns 10,424,473 shares of the biotechnology company’s stock valued at $13,763,000 after acquiring an additional 1,995,633 shares in the last quarter. Millennium Management LLC lifted its position in shares of OPKO Health by 39.2% in the 1st quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company’s stock worth $10,602,000 after acquiring an additional 1,798,385 shares during the period. Finally, Goldman Sachs Group Inc. lifted its position in shares of OPKO Health by 4.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,001,214 shares of the biotechnology company’s stock worth $6,642,000 after acquiring an additional 161,394 shares during the period. Institutional investors own 64.63% of the company’s stock.

Wall Street Analysts Forecast Growth

OPK has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. started coverage on OPKO Health in a research report on Thursday. They set a “neutral” rating for the company. Barrington Research reaffirmed an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a report on Thursday, October 30th. Jefferies Financial Group reiterated a “hold” rating and issued a $1.60 target price (down previously from $2.00) on shares of OPKO Health in a report on Thursday, October 30th. Zacks Research raised shares of OPKO Health from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OPKO Health in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, OPKO Health has an average rating of “Hold” and an average price target of $2.28.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.